[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576772":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":29,"locations":24,"responsibleParty":35,"collaborators":24,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":24,"maxAge":46,"enrollmentInfo":47,"targetDuration":24,"studyType":50,"phases":51,"briefSummary":11,"conditions":53,"keywords":24,"overallStatus":55,"whyStopped":24,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":24},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventional","EXPERIMENTAL","Vitamin C will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations\n\nInflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups",[13],"Other: Vitamin C",{"label":15,"type":16,"description":17,"interventionNames":18},"The control group","PLACEBO_COMPARATOR","A placebo will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations\n\nInflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups",[19],"Other: Placebo",[21,25],{"type":6,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"Vitamin C",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Placebo","Placebo will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations\n\nInflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Hoda Atef Abdelsattar Ibrahim","CONTACT","hodaibrahim424@gmail.com","hodaibrahim4242@gmail.com",{"type":36,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","100576772","impact-of-vitamin-c-supplementation-on-hospital-outcomes-in-children-undergoing-corrective-heart-surgery-for-congenital-heart-diseases-100576772",false,"NCT06789640","Impact of Vitamin C Supplementation on Hospital Outcomes in Children Undergoing Corrective Heart Surgery for Congenital Heart Diseases","Impact of Vitamin C Supplementation on the Hospital Outcomes in Children Undergoing Corrective Heart Surgery for Congenital Heart Diseases","RCT","Inclusion Criteria:\n\n* Children in the first two years who will be for corrective surgery for heart diseases congenital heart diseases\n* Pediatric patients whose parents or caregivers agree to be enrolled in the study.\n* Risk Adjustment for Congenital Heart Surgery -1 (RACHS-1) for Evaluation of Mortality in Children Undergoing Cardiac Surgery : the first two categories (Thiagarajan and C. Laussen 2015)\n\nExclusion Criteria:\n\n* Pediatric patients with associated comorbid conditions.","ALL","7 Years",{"count":48,"type":49},20,"ESTIMATED","INTERVENTIONAL",[52],"NA",[54],"Congenital Heart Disease (CHD)","NOT_YET_RECRUITING","2025-02-13",{"date":58,"type":59},"2025-02-17","ACTUAL",{"date":61,"type":49},"2025-02-19",{"date":63,"type":49},"2025-04-19",{"name":5,"class":6}]